Once again at DDW®, ASGE has partnered with international gastroenterology societies to plan several joint sessions that showcase endoscopic advances around the world.
Avinash G. Ketwaroo, MD, walks through sessions designed to meet the unique needs of DDW® attendees in the early stages of their careers in gastrointestinal medicine.
SSAT is offering a full slate of original research at DDW® across nine Quick Shot sessions. Each 90-minute session will showcase 10 to 15 unique studies — more than 100 presentations across all of the Quick Shot sessions, says Michael G. House, MD, FACS.
Will you be pinched for time at #DDW19? AGA’s Postgraduate Course course provides a concise and comprehensive update on the latest medical, scientific and technological advances in gastroenterology from the previous 12 months, designed for attendees who have limited time. Joseph Ahn, MD, MS, MBA, AGAF, and course co-directors explain more.
Grace H. Elta, MD, AGAF, FASGE, will co-moderate Monday’s ASGE Clinical Symposium Pancreatic Duct Endotherapy: Caution or Full Steam Ahead, which will review the current science and best practices for endotherapy in pancreatitis treatment.
Suresh Chari, MD, examined the medical and nutritional therapies for pain management in an ASGE Clinical Symposium on Sunday morning. “Pain is processed in some of the same areas of the brain as thoughts and emotions — structural damage or inflammation are not essential to experience pain,” Dr. Chari said.
When developing programming for DDW® 2018, the SSAT Program Committee aimed to create a broad array of options to meet the demands of society members and DDW attendees of all interests and skill levels, according to SSAT Program Committee Chair Vic Velanovich, MD.
During Sunday’s ASGE Clinical Symposium ERCP: Staying Out of Trouble Situations, four experts will offer practical advice for overcoming common challenges when performing endoscopic retrograde cholangiopancreatography (ERCP).
By 2030, pancreatic cancer is projected to be the second-leading cause of cancer death, according to an estimate by SSAT and the Americas Hepato-Pancreato-Biliary Association (AHPBA).
Growing evidence suggests that pancreatic neuroendocrine tumors (PNET) are more common than previously thought. Four experts will discuss the latest data during Sunday’s DDW Clinical Symposium Recent Advances in Neuroendocrine Tumors of the Pancreas, which is jointly sponsored by AGA and SSAT.
